Smith & Nephew SNATS, Inc. (SNN) – What Are Analysts Saying About This Stock?

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been assigned a consensus rating of “Hold” from the eleven analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $31.91.

SNN has been the topic of several recent research reports. Weiss Ratings downgraded Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Wall Street Zen upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research report on Sunday, September 13th. Berenberg Bank set a $33.88 target price on shares of Smith & Nephew SNATS in a research note on Friday, September 11th. Barclays downgraded shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded shares of Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 8th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SNN. BlackRock Inc. acquired a new stake in Smith & Nephew SNATS during the second quarter valued at approximately $505,323,000. River Road Asset Management LLC raised its stake in shares of Smith & Nephew SNATS by 13.8% in the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after buying an additional 384,926 shares in the last quarter. Bank of America Corp DE bought a new position in Smith & Nephew SNATS during the second quarter valued at about $97,223,000. Bank of New York Mellon Corp acquired a new position in Smith & Nephew SNATS during the second quarter worth about $89,325,000. Finally, Caisse de depot et placement du Quebec acquired a new position in Smith & Nephew SNATS during the second quarter worth about $64,186,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Performance

Shares of SNN stock opened at $29.05 on Friday. The stock’s 50-day moving average is $28.26 and its two-hundred day moving average is $30.01. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS has a 1 year low of $26.12 and a 1 year high of $37.51.

Smith & Nephew SNATS Announces Dividend

The company also recently declared a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a dividend of $0.3120 per share. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 236.0%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company headquartered in Watford, England. Founded in 1856 by pharmacist Thomas James Smith in Hull, the company has grown from a pharmacy business into a provider of surgical and wound-care products for healthcare professionals and patients.

The company operates through three principal areas: Orthopaedics, Sports Medicine, and Advanced Wound Management. Its products include joint-replacement systems, trauma and extremity devices, arthroscopy equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products used to support healing and tissue recovery.

Smith & Nephew serves hospitals, clinics, surgeons, and patients in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific, and other international regions.